No excess mortality up to 10 years in early stages of breast cancer in women adherent to oral endocrine therapy: A probabilistic graphical modeling approach

Breast cancer (BC) is globally the most frequent cancer in women. Adherence to endocrine therapy (ET) in hormone-receptor-positive BC patients is active and voluntary for the first five years after diagnosis. This study examines the impact of adherence to ET on 10-year excess mortality (EM) in patie...

ver descrição completa

Detalhes bibliográficos
Autores: Clèries, Ramón, Buxó, Maria, Vilardell, Mireia, Ameijide, Alberto, Martínez Martínez, José Miguel|||0000-0002-9633-1204, Font, Rebeca, Marcos Gragera, Rafael, Puigdemont Guinart, Montse, Viñas Villaró, Gemma, Carulla Areste, Marià, Espinás, Josep Alfons, Galceràn Padrós, Jaume, Izquierdo, Angel, Borrás Andrés, José Maria
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Universitat Politècnica de Catalunya (UPC)
Repositorio:UPCommons. Portal del coneixement obert de la UPC
Idioma:inglés
OAI Identifier:oai:upcommons.upc.edu:2117/367303
Acesso em linha:https://hdl.handle.net/2117/367303
https://dx.doi.org/10.3390/ijerph19063605
Access Level:acceso abierto
Palavra-chave:Breas t-- Cancer
Hormone therapy
Graphical modeling (Statistics)
Breast cancer
Excess mortality
Adherence
Endocrine therapy
Synthetic dataset
Graphical modeling
Mama -- Càncer
Hormonoteràpia
Modelització gràfica (Estadística)
Àrees temàtiques de la UPC::Ciències de la salut::Medicina
Descrição
Resumo:Breast cancer (BC) is globally the most frequent cancer in women. Adherence to endocrine therapy (ET) in hormone-receptor-positive BC patients is active and voluntary for the first five years after diagnosis. This study examines the impact of adherence to ET on 10-year excess mortality (EM) in patients diagnosed with Stages I to III BC (N = 2297). Since sample size is an issue for estimating age- and stage-specific survival indicators, we developed a method, ComSynSurData, for generating a large synthetic dataset (SynD) through probabilistic graphical modeling of the original cohort. We derived population-based survival indicators using a Bayesian relative survival model fitted to the SynD. Our modeling showed that hormone-receptor-positive BC patients diagnosed beyond 49 years of age at Stage I or beyond 59 years at Stage II do not have 10-year EM if they follow the prescribed ET regimen. This result calls for developing interventions to promote adherence to ET in patients with hormone receptor-positive BC and in turn improving cancer survival. The presented methodology here demonstrates the potential use of probabilistic graphical modeling for generating reliable synthetic datasets for validating population-based survival indicators when sample size is an issue.

Registos relacionados